Developer docs
API playgroundTry for free, no card

Search company profiles

OmniAb

Full company profile

uuid00006cn

Namestring
OmniAb
Legal namestring
OmniAb, Inc.
Websiteurl
omniab.com
Company typeenum
Public
Founded yearint
2022
Descriptiontext

OmniAb, Inc. provides pharmaceutical and biotechnology companies with access to a proprietary antibody discovery platform built on multiple genetically engineered transgenic animal systems — including OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra, OmniFlic, OmniClic, and Omni*dAb* — that produce fully human antibody repertoires across diverse host species and structural motifs. These biological intelligence (BI)-powered repertoires are paired with the xPloration high-throughput microfluidic single B-cell screening platform, the Ab Initio computational antigen design capability, in silico discovery tools operated from its Oro Valley, AZ center, Fc-silencing antibody optimization, and a dedicated ion channel and transporter research capability (Icagen) in Durham, NC. The platform supports discovery across multiple therapeutic modalities including traditional antibodies, bispecifics, antibody-drug conjugates, CAR-T, radioligands, and picobodies, with three OmniAb-derived antibodies already securing regulatory approvals (zimberelimab and sugemalimab in China; TECVAYLI in the EU).

OmniAb operates a sales-led, enterprise licensing business model, distributing its technology through direct business development relationships with biopharma partners and co-discovery engagements. Revenue is generated through upfront license fees, milestone payments triggered by partner program achievements (such as the $10M TECVAYLI European commercial sale milestone), service fees for antibody discovery work performed, and royalties on commercial sales for agreements that include them (notably, the TECVAYLI/Janssen agreement does not include royalties). Pricing is quote-based and multi-year, with terms customized per partner. The customer base spans 107 active partners running 409 active programs, of which 32 are in clinical development or commercialization, distributed across large pharma (Janssen, Teva, Merck KGaA), mid-cap and emerging biotechs (Immunovant, CStone, Gloria Biosciences, HanAll, Veraxa, Mabtrx), and academic institutions (Memorial Sloan Kettering, Dana Farber).

The company originated as the antibody discovery business of Ligand Pharmaceuticals and became an independent publicly traded entity in November 2022 via a Reverse Morris Trust spin-off and business combination with Avista Public Acquisition Corp. II, listing on Nasdaq under ticker OABI at an $850 million pre-money equity valuation. Headquartered in Emeryville, California, with additional R&D sites in Durham, NC and Oro Valley, AZ, OmniAb reported FY2025 revenue of $18.7M (a decline from $26.4M in FY2024) followed by Q1 2026 revenue of $14.4M representing 243% YoY growth, prompting management to raise full-year 2026 guidance to $28–33M. The company is unprofitable, with a FY2025 net loss of $64.8M, but held approximately $60M in cash with no debt as of September 2025 and reduced cash burn by approximately 25% year-over-year.

Short descriptiontext

OmniAb, Inc. licenses proprietary transgenic antibody discovery platforms — including OmniRat, OmniMouse, OmniChicken, OmniTaur, and OmniUltra — paired with xPloration single B-cell screening and Ab Initio antigen design, to pharmaceutical and biotechnology partners developing next-generation therapeutics across multiple modalities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic antibody discovery, transgenic antibody platforms, bispecific antibody engineering, single B-cell screening, biopharma technology licensing
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Therapeutic Antibody Discovery
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Upfront License Fees
TypeOne Time License
Description

One-time upfront payments received upon execution of license agreements with partners accessing OmniAb's antibody discovery technology. Recorded as license revenue when recognized.

businesswire.com
2Milestone Payments
TypeLicensing Royalties
Description

Contractual milestone payments triggered by partner program achievements such as regulatory approvals (e.g., $10M milestone upon first commercial sale of TECVAYLI in Europe) and clinical/development progression. Milestone revenue drove Q1 2026 revenue of $14.4M, a 243% increase year-over-year.

businesswire.com
3Service Revenue
TypeProfessional Services
Description

Revenue earned from performing antibody discovery and related research services for partners using OmniAb's platforms and capabilities. Decreased in 2025 versus 2024.

businesswire.com
4Royalties on Commercial Sales
TypeLicensing Royalties
Description

Recurring royalty revenue tied to commercial sales of approved OmniAb-derived therapeutic products by partners. Note: not all license agreements include royalties (e.g., the OmniAb/Janssen license for TECVAYLI does not include royalty payments to OmniAb). Royalty revenue represents a future, milestone-driven stream as more partnered programs reach commercialization.

simplywall.st
5xPloration® Partner Access Program Fees
TypeUsage Based
Description

Program introduced in May 2025 enabling partners to access xPloration's high-throughput single B-cell screening capabilities in their own laboratories; expected to generate service/program fees.

in.investing.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based technology licensing and discovery services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies per partner agreement; includes upfront fees, milestones, and in some cases royalties on commercial sales. Not publicly listed.

omniab.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 9 records shown
1OmniUltra
Description

Transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework, extending into peptide therapeutics for bispecifics, CAR-T, radioligands, and picobody discovery; launched December 2025.

markets.financialcontent.com
+8 more records
Core offering1 text field

OmniAb licenses an integrated therapeutic antibody discovery platform to pharmaceutical and biotechnology partners. Its foundation is a suite of proprietary transgenic animal platforms — OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra and Omni*dAb*, plus OmniFlic/OmniClic for bispecifics — that produce diverse fully human antibody repertoires. These are paired with the xPloration high-throughput single B-cell screening platform, Ab Initio computational antigen design, in silico NGS repertoire mining, Fc-silencing optimization, and an established ion channel/transporter (Icagen) capability to deliver end-to-end antibody discovery across modalities including bispecifics, ADCs, CAR-T, radioligands and picobodies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 243% year-over-year revenue increase in Q1 2026 ($14.4M)
+5 more records
Product overview1 text field

OmniAb offers a single integrated therapeutic antibody discovery platform rather than standalone point products. At the core are multiple proprietary transgenic animal platforms — OmniRat, OmniMouse, OmniChicken, Omni*dAb*, OmniUltra, and OmniTaur — which together generate diverse fully human antibody repertoires, with OmniFlic and OmniClic extending this into common-light-chain bispecific applications. These biological intelligence (BI)-powered repertoires are paired with the xPloration high-throughput single B-cell screening platform, the Ab Initio computational Antigen Design module, the broader In Silico Technologies suite, Fc-Silencing Technology for Antibody Optimization, and an Ion Channel and Transporter (Icagen) capability, all delivered to partners through licensing and services agreements plus the xPloration Partner Access Program.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierCoreTypeOthersAnnounced on2026-06-19
Description

Ratified as OmniAb's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026 Annual Meeting of Shareholders, with 102,163,551 votes in favor and only 112,653 votes against.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-06
Description

Immunovant is a partner developing OmniAb-discovered antibodies including batoclimab (Phase 3 in thyroid eye disease) and IMVT-1402 (Phase 2/3). Reported R&D progress in Q4 2025 earnings; topline data expected through 2026-2027. Phase 3 failure of batoclimab in thyroid eye disease did not impact OmniAb's analyst outlook.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-06
Description

Teva is a partner with program TEV-408 progressing through Phase 1/2 trials; reported R&D progress in Q4 2025 earnings and subsequent quarters with topline data expected.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-06
Description

Merck KGaA is a partner with an OmniAb-derived program progressing through R&D; reported R&D progress in Q4 2025 earnings and subsequent quarters.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Technology license and services agreement for antibody discovery using OmniAb's technology. Revenue, potential equity, and royalties are involved in the arrangement. Mabtrx Biosciences is a newly-formed incubated company of ArrowMark Partners and Viking Global Investors.

Strategic tierTransactionalTypeOthersAnnounced on2025-08-25
Description

Latham & Watkins LLP advised OmniAb on the $30 million private placement announced August 2025. Legal counsel role in capital markets transaction.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Co-discovery alliance to develop a novel bispecific antibody-drug conjugate (bsADC) program targeting solid tumors. Combines OmniAb's transgenic antibody discovery technology with Veraxa's proprietary ADC linker and conjugation expertise. Resulting bsADC program is jointly owned by both parties, with shared future revenues from development, licensing, and commercialization. Described as Veraxa's second major strategic collaboration within six months.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-02-28
Description

Collaboration on antibody research using OmniAb's antibody discovery technology. Reported as a research collaboration agreement; details of the partnership scope and economics were not disclosed in the available source.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-09
Description

Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; one of multiple new partner agreements cited by CEO Matt Foehr as a record year for deal flow.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-09
Description

Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-09
Description

Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings in 2024.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-09
Description

Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-08-09
Description

Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; one of the academic/research institution partners disclosed in 2024 deal flow.

14Redwood Bioscience
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-08-09
Description

Entered a joint agreement with OmniAb in 2024 for antibody research collaboration; one of the partnerships cited as supporting record deal flow in 2024.

biopharmaapac.com
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-08-24
Description

Janssen discovered TECVAYLI (teclistamab) — a BCMA x CD3 bispecific antibody — using OmniAb's OmniRat antibody discovery technology. TECVAYLI received European Commission conditional marketing authorization in August 2022 (first European approval of an OmniAb-derived antibody and first OmniAb-derived bispecific). OmniAb is eligible for a $10M milestone payment upon first commercial sale in the UK, Italy, Germany, France, or Spain. Note: the license agreement with CNA Development LLC does not include royalty payments to OmniAb.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-03-23
Description

OmniAb was spun off from Ligand Pharmaceuticals through a Reverse Morris Trust transaction with Avista Public Acquisition Corp. II (APAC), closing on November 1, 2022 with regular-way trading beginning November 2, 2022 on Nasdaq under ticker 'OABI'. Ligand contributed $15M to OmniAb; Ligand shareholders received 100% of Ligand's shares in OmniAb through a tax-free distribution. Ligand shareholders were expected to own approximately 75% of the combined entity.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-12-22
Description

CStone developed sugemalimab (Cejemly), an anti-PD-L1 monoclonal antibody discovered using OmniAb's OmniRat platform. Received NMPA approval in China for first-line treatment of metastatic NSCLC in combination with chemotherapy in December 2021; subsequent clinical programs in R/R ENKTL, gastric, and esophageal cancers.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-08-30
Description

Gloria Biosciences received NMPA approval in China for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody, for recurrent or refractory classical Hodgkin's lymphoma — the first regulatory approval of an OmniAb-derived antibody. GloriaBio holds development and commercialization rights in China via a sublicense with Wuxi Biologics Ireland Limited.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Adimab is a private antibody discovery platform company offering yeast- and mammalian-based discovery services to biopharma partners under a similar licensing/services/milestone model. Most direct functional comparable to OmniAb in business model and customer base.

TypeDirect peer
Description

AbCellera is a public antibody discovery platform (Nasdaq: ABCL) that uses single B-cell screening, similar to OmniAb's xPloration, and licenses to pharma partners. Directly comparable in target market (biopharma antibody discovery) and business model (licensing + milestones + royalties).

TypeBroad incumbent
Description

Ligand is OmniAb's former parent and operates a similar technology-licensing and royalty business model across multiple platforms (Captisol, OmniAb legacy, others). Comparable as a publicly traded platform-licensing biotech, though more diversified beyond antibodies.

TypeBroad incumbent
Description

Charles River offers a broad suite of CRO and discovery services, including biologics and antibody-related capabilities (e.g., Distributed Bio, Retrogenix). It is a comparable enterprise-scale services provider to biopharma, though antibody discovery is one of many service lines.

TypeBroad incumbent
Description

WuXi Biologics is a global contract biologics manufacturer and discovery services provider. It overlaps with OmniAb's biopharma services customer base and serves as a broad incumbent in the biologics discovery/CDMO space.

TypeDirect peer
Description

AnaptysBio is a clinical-stage antibody company with an in-house discovery platform that it has also historically partnered with pharma. Comparable as a publicly traded antibody-discovery platform company serving the same biopharma partner base.

TypeEmerging player
Description

Ginkgo is a public cell programming and biosecurity platform company. While not a direct antibody peer, it is comparable as a publicly traded platform-licensing biology business pursuing enterprise biopharma and broader life sciences customers.

TypeEmerging player
Description

Generate is a privately held AI/ML-driven generative biology company developing programmable antibodies and peptides. Comparable as an emerging player in the antibody/peptide discovery space that could overlap with OmniUltra's peptide and next-generation modality ambitions.

TypeOthers
Description

Bio-Techne is a publicly traded life sciences research tools and diagnostics company that supplies reagents, proteins, and antibodies to the same biopharma research customers. Comparable as an ecosystem enabler serving antibody discovery workflows, though not a direct platform competitor.

TypeEmerging player
Description

Crescendo is a private T cell engager and multi-modality antibody platform company (e.g., Humabody V_H). Comparable as an emerging player in next-generation antibody modalities (single-domain, bispecifics) that intersects with OmniAb's Omni*dAb* and bispecific platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature14 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OmniAb

Therapeutic Antibody Discoveryomniab.com

OmniAb, Inc. licenses proprietary transgenic antibody discovery platforms — including OmniRat, OmniMouse, OmniChicken, OmniTaur, and OmniUltra — paired with xPloration single B-cell screening and Ab Initio antigen design, to pharmaceutical and biotechnology partners developing next-generation therapeutics across multiple modalities.

What OmniAb does

OmniAb, Inc. provides pharmaceutical and biotechnology companies with access to a proprietary antibody discovery platform built on multiple genetically engineered transgenic animal systems — including OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra, OmniFlic, OmniClic, and Omni*dAb* — that produce fully human antibody repertoires across diverse host species and structural motifs. These biological intelligence (BI)-powered repertoires are paired with the xPloration high-throughput microfluidic single B-cell screening platform, the Ab Initio computational antigen design capability, in silico discovery tools operated from its Oro Valley, AZ center, Fc-silencing antibody optimization, and a dedicated ion channel and transporter research capability (Icagen) in Durham, NC. The platform supports discovery across multiple therapeutic modalities including traditional antibodies, bispecifics, antibody-drug conjugates, CAR-T, radioligands, and picobodies, with three OmniAb-derived antibodies already securing regulatory approvals (zimberelimab and sugemalimab in China; TECVAYLI in the EU).

OmniAb operates a sales-led, enterprise licensing business model, distributing its technology through direct business development relationships with biopharma partners and co-discovery engagements. Revenue is generated through upfront license fees, milestone payments triggered by partner program achievements (such as the $10M TECVAYLI European commercial sale milestone), service fees for antibody discovery work performed, and royalties on commercial sales for agreements that include them (notably, the TECVAYLI/Janssen agreement does not include royalties). Pricing is quote-based and multi-year, with terms customized per partner. The customer base spans 107 active partners running 409 active programs, of which 32 are in clinical development or commercialization, distributed across large pharma (Janssen, Teva, Merck KGaA), mid-cap and emerging biotechs (Immunovant, CStone, Gloria Biosciences, HanAll, Veraxa, Mabtrx), and academic institutions (Memorial Sloan Kettering, Dana Farber).

The company originated as the antibody discovery business of Ligand Pharmaceuticals and became an independent publicly traded entity in November 2022 via a Reverse Morris Trust spin-off and business combination with Avista Public Acquisition Corp. II, listing on Nasdaq under ticker OABI at an $850 million pre-money equity valuation. Headquartered in Emeryville, California, with additional R&D sites in Durham, NC and Oro Valley, AZ, OmniAb reported FY2025 revenue of $18.7M (a decline from $26.4M in FY2024) followed by Q1 2026 revenue of $14.4M representing 243% YoY growth, prompting management to raise full-year 2026 guidance to $28–33M. The company is unprofitable, with a FY2025 net loss of $64.8M, but held approximately $60M in cash with no debt as of September 2025 and reduced cash burn by approximately 25% year-over-year.

OmniAb firmographics

Firmographics
Name
OmniAb
Legal name
OmniAb, Inc.
Website
https://omniab.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
OmniAb, Inc. licenses proprietary transgenic antibody discovery platforms — including OmniRat, OmniMouse, OmniChicken, OmniTaur, and OmniUltra — paired with xPloration single B-cell screening and Ab Initio antigen design, to pharmaceutical and biotechnology partners developing next-generation therapeutics across multiple modalities.
Ownership category
akta.pro rank

OmniAb industry classification

Industry
Product category
Therapeutic Antibody Discovery
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Therapeutic antibody discovery
  • Transgenic antibody platforms
  • Bispecific antibody engineering
  • Single B-cell screening
  • Biopharma technology licensing

Where OmniAb is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices3 records

Markets served

OmniAb business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Upfront License Fees: One-time upfront payments received upon execution of license agreements with partners accessing OmniAb's antibody discovery technology. Recorded as license revenue when recognized.
  2. Milestone Payments: Contractual milestone payments triggered by partner program achievements such as regulatory approvals (e.g., $10M milestone upon first commercial sale of TECVAYLI in Europe) and clinical/development progression. Milestone revenue drove Q1 2026 revenue of $14.4M, a 243% increase year-over-year.
  3. Service Revenue: Revenue earned from performing antibody discovery and related research services for partners using OmniAb's platforms and capabilities. Decreased in 2025 versus 2024.
  4. Royalties on Commercial Sales: Recurring royalty revenue tied to commercial sales of approved OmniAb-derived therapeutic products by partners. Note: not all license agreements include royalties (e.g., the OmniAb/Janssen license for TECVAYLI does not include royalty payments to OmniAb). Royalty revenue represents a future, milestone-driven stream as more partnered programs reach commercialization.
  5. xPloration® Partner Access Program Fees: Program introduced in May 2025 enabling partners to access xPloration's high-throughput single B-cell screening capabilities in their own laboratories; expected to generate service/program fees.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based technology licensing and discovery services

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

OmniAb product offering

Product offering

Core offering

OmniAb licenses an integrated therapeutic antibody discovery platform to pharmaceutical and biotechnology partners. Its foundation is a suite of proprietary transgenic animal platforms — OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra and Omni*dAb*, plus OmniFlic/OmniClic for bispecifics — that produce diverse fully human antibody repertoires. These are paired with the xPloration high-throughput single B-cell screening platform, Ab Initio computational antigen design, in silico NGS repertoire mining, Fc-silencing optimization, and an established ion channel/transporter (Icagen) capability to deliver end-to-end antibody discovery across modalities including bispecifics, ADCs, CAR-T, radioligands and picobodies.

Product overview

OmniAb offers a single integrated therapeutic antibody discovery platform rather than standalone point products. At the core are multiple proprietary transgenic animal platforms — OmniRat, OmniMouse, OmniChicken, Omni*dAb*, OmniUltra, and OmniTaur — which together generate diverse fully human antibody repertoires, with OmniFlic and OmniClic extending this into common-light-chain bispecific applications. These biological intelligence (BI)-powered repertoires are paired with the xPloration high-throughput single B-cell screening platform, the Ab Initio computational Antigen Design module, the broader In Silico Technologies suite, Fc-Silencing Technology for Antibody Optimization, and an Ion Channel and Transporter (Icagen) capability, all delivered to partners through licensing and services agreements plus the xPloration Partner Access Program.

Differentiator

Problem solved

Functional benefit

Brands

  • OmniUltra: Transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework, extending into peptide therapeutics for bispecifics, CAR-T, radioligands, and picobody discovery; launched December 2025.
  • OmniRat
  • OmniMouse
  • OmniChicken
  • OmniTaur
  • Omni*dAb*
  • OmniFlic
  • OmniClic
  • xPloration

Quantifiable outcome

  • 243% year-over-year revenue increase in Q1 2026 ($14.4M)
  • +5 more outcomes

Companies that use OmniAb

Customer profile

Named customers16 records

Segments3 records

Ideal customer profiles3 records

OmniAb technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability7 records

Feature14 records

OmniAb partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core, major, transactional, minor and flagship.

  • Ernst & Young LLPcoreOthers · 19 June 2026Ratified as OmniAb's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026 Annual Meeting of Shareholders, with 102,163,551 votes in favor and only 112,653 votes against.
  • ImmunovantmajorOEM/ Whitelabel/ Licensing Partner · 6 March 2026Immunovant is a partner developing OmniAb-discovered antibodies including batoclimab (Phase 3 in thyroid eye disease) and IMVT-1402 (Phase 2/3). Reported R&D progress in Q4 2025 earnings; topline data expected through 2026-2027. Phase 3 failure of batoclimab in thyroid eye disease did not impact OmniAb's analyst outlook.
  • Teva Pharmaceutical IndustriesmajorOEM/ Whitelabel/ Licensing Partner · 6 March 2026Teva is a partner with program TEV-408 progressing through Phase 1/2 trials; reported R&D progress in Q4 2025 earnings and subsequent quarters with topline data expected.
  • Merck KGaAmajorOEM/ Whitelabel/ Licensing Partner · 6 March 2026Merck KGaA is a partner with an OmniAb-derived program progressing through R&D; reported R&D progress in Q4 2025 earnings and subsequent quarters.
  • Mabtrx Biosciences (subsidiary of AMVKG LS, a JV between ArrowMark Partners and Viking Global Investors)coreStrategic or Co-development Partner · 18 November 2025Technology license and services agreement for antibody discovery using OmniAb's technology. Revenue, potential equity, and royalties are involved in the arrangement. Mabtrx Biosciences is a newly-formed incubated company of ArrowMark Partners and Viking Global Investors.
  • Latham & Watkins LLPtransactionalOthers · 25 August 2025Latham & Watkins LLP advised OmniAb on the $30 million private placement announced August 2025. Legal counsel role in capital markets transaction.
  • Veraxa Biotech AGcoreStrategic or Co-development Partner · 1 May 2025Co-discovery alliance to develop a novel bispecific antibody-drug conjugate (bsADC) program targeting solid tumors. Combines OmniAb's transgenic antibody discovery technology with Veraxa's proprietary ADC linker and conjugation expertise. Resulting bsADC program is jointly owned by both parties, with shared future revenues from development, licensing, and commercialization. Described as Veraxa's second major strategic collaboration within six months.
  • Chiome BioscienceminorStrategic or Co-development Partner · 28 February 2025Collaboration on antibody research using OmniAb's antibody discovery technology. Reported as a research collaboration agreement; details of the partnership scope and economics were not disclosed in the available source.
  • DAAN BiominorOEM/ Whitelabel/ Licensing Partner · 9 August 2024Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; one of multiple new partner agreements cited by CEO Matt Foehr as a record year for deal flow.
  • Topaz TherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 9 August 2024Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings.
  • HanAll BiopharmaminorOEM/ Whitelabel/ Licensing Partner · 9 August 2024Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings in 2024.
  • 92BiominorOEM/ Whitelabel/ Licensing Partner · 9 August 2024Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings.
  • Memorial Sloan Kettering Cancer CenterminorOEM/ Whitelabel/ Licensing Partner · 9 August 2024Signed a new platform license agreement with OmniAb in 2024 for antibody discovery; one of the academic/research institution partners disclosed in 2024 deal flow.
  • Redwood BioscienceminorStrategic or Co-development Partner · 9 August 2024Entered a joint agreement with OmniAb in 2024 for antibody research collaboration; one of the partnerships cited as supporting record deal flow in 2024.
  • Janssen Biotech (Johnson & Johnson)flagshipOEM/ Whitelabel/ Licensing Partner · 24 August 2022Janssen discovered TECVAYLI (teclistamab) — a BCMA x CD3 bispecific antibody — using OmniAb's OmniRat antibody discovery technology. TECVAYLI received European Commission conditional marketing authorization in August 2022 (first European approval of an OmniAb-derived antibody and first OmniAb-derived bispecific). OmniAb is eligible for a $10M milestone payment upon first commercial sale in the UK, Italy, Germany, France, or Spain. Note: the license agreement with CNA Development LLC does not include royalty payments to OmniAb.
  • Ligand PharmaceuticalsflagshipStrategic or Co-development Partner · 23 March 2022OmniAb was spun off from Ligand Pharmaceuticals through a Reverse Morris Trust transaction with Avista Public Acquisition Corp. II (APAC), closing on November 1, 2022 with regular-way trading beginning November 2, 2022 on Nasdaq under ticker 'OABI'. Ligand contributed $15M to OmniAb; Ligand shareholders received 100% of Ligand's shares in OmniAb through a tax-free distribution. Ligand shareholders were expected to own approximately 75% of the combined entity.
  • CStone PharmaceuticalsmajorOEM/ Whitelabel/ Licensing Partner · 22 December 2021CStone developed sugemalimab (Cejemly), an anti-PD-L1 monoclonal antibody discovered using OmniAb's OmniRat platform. Received NMPA approval in China for first-line treatment of metastatic NSCLC in combination with chemotherapy in December 2021; subsequent clinical programs in R/R ENKTL, gastric, and esophageal cancers.
  • Gloria BiosciencesmajorOEM/ Whitelabel/ Licensing Partner · 30 August 2021Gloria Biosciences received NMPA approval in China for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody, for recurrent or refractory classical Hodgkin's lymphoma — the first regulatory approval of an OmniAb-derived antibody. GloriaBio holds development and commercialization rights in China via a sublicense with Wuxi Biologics Ireland Limited.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

OmniAb competitors and assessment

Company assessment

Direct peers

  • Adimab: Adimab is a private antibody discovery platform company offering yeast- and mammalian-based discovery services to biopharma partners under a similar licensing/services/milestone model. Most direct functional comparable to OmniAb in business model and customer base.
  • AbCellera Biologics: AbCellera is a public antibody discovery platform (Nasdaq: ABCL) that uses single B-cell screening, similar to OmniAb's xPloration, and licenses to pharma partners. Directly comparable in target market (biopharma antibody discovery) and business model (licensing + milestones + royalties).
  • AnaptysBio: AnaptysBio is a clinical-stage antibody company with an in-house discovery platform that it has also historically partnered with pharma. Comparable as a publicly traded antibody-discovery platform company serving the same biopharma partner base.

Broad incumbents

  • Ligand Pharmaceuticals: Ligand is OmniAb's former parent and operates a similar technology-licensing and royalty business model across multiple platforms (Captisol, OmniAb legacy, others). Comparable as a publicly traded platform-licensing biotech, though more diversified beyond antibodies.
  • Charles River Laboratories: Charles River offers a broad suite of CRO and discovery services, including biologics and antibody-related capabilities (e.g., Distributed Bio, Retrogenix). It is a comparable enterprise-scale services provider to biopharma, though antibody discovery is one of many service lines.
  • WuXi Biologics: WuXi Biologics is a global contract biologics manufacturer and discovery services provider. It overlaps with OmniAb's biopharma services customer base and serves as a broad incumbent in the biologics discovery/CDMO space.

Emerging players

  • Ginkgo Bioworks: Ginkgo is a public cell programming and biosecurity platform company. While not a direct antibody peer, it is comparable as a publicly traded platform-licensing biology business pursuing enterprise biopharma and broader life sciences customers.
  • Generate Biomedicines: Generate is a privately held AI/ML-driven generative biology company developing programmable antibodies and peptides. Comparable as an emerging player in the antibody/peptide discovery space that could overlap with OmniUltra's peptide and next-generation modality ambitions.
  • Crescendo Biologics: Crescendo is a private T cell engager and multi-modality antibody platform company (e.g., Humabody V_H). Comparable as an emerging player in next-generation antibody modalities (single-domain, bispecifics) that intersects with OmniAb's Omni*dAb* and bispecific platforms.

Others

  • Bio-Techne: Bio-Techne is a publicly traded life sciences research tools and diagnostics company that supplies reagents, proteins, and antibodies to the same biopharma research customers. Comparable as an ecosystem enabler serving antibody discovery workflows, though not a direct platform competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

OmniAb social profiles

Digital presence

OmniAb compliance and trust

Trust signal

Compliance5 records

OmniAb financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OmniAb leadership team

Management profile

Number of profiles

Profiles6 records

OmniAb subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OmniAb funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OmniAb M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OmniAb

What does OmniAb do?

OmniAb licenses an integrated therapeutic antibody discovery platform to pharmaceutical and biotechnology partners. Its foundation is a suite of proprietary transgenic animal platforms — OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra and Omni*dAb*, plus OmniFlic/OmniClic for bispecifics — that produce diverse fully human antibody repertoires. These are paired with the xPloration high-throughput single B-cell screening platform, Ab Initio computational antigen design, in silico NGS repertoire mining, Fc-silencing optimization, and an established ion channel/transporter (Icagen) capability to deliver end-to-end antibody discovery across modalities including bispecifics, ADCs, CAR-T, radioligands and picobodies.

Is OmniAb a public or private company?

OmniAb is a public company. It is classified as public and is currently operating.

When was OmniAb founded?

OmniAb was founded in 2022. It employs 51 to 100 people.

Where is OmniAb based?

OmniAb is headquartered in Emeryville, United States, in the North America region.

How does OmniAb make money?

Five revenue lines are on record. Upfront License Fees are the primary driver. The others are milestone Payments, service Revenue, royalties on Commercial Sales and xPloration® Partner Access Program Fees.

Who are OmniAb's main competitors?

Direct peers on record are Adimab, AbCellera Biologics and AnaptysBio. Broad incumbents are Ligand Pharmaceuticals, Charles River Laboratories and WuXi Biologics. Emerging players are Ginkgo Bioworks, Generate Biomedicines and Crescendo Biologics. Bio-Techne is listed as an others.

Does OmniAb have an API?

No public API is recorded for OmniAb.

What industry is OmniAb in?

OmniAb's product category is Therapeutic Antibody Discovery. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 3254 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsOmniAb Q3 Earnings Call HighlightsOmniAb reported Q3 revenue of $4.0 million, up from $2.2 million, and raised its 2026 revenue guidance to $35-39 million. The company posted a Q3 net loss of $15.7 million, narrowing from $16.5 million a year earlier, and expects to finish 2026 with $53-57 million in cash.YahooOmniAb (OABI) Q3 Results Keep Cash Progress In FocusOmniAb reported Q3 2026 net loss of $15.7 million and revenue of $4.0 million, with EPS down to $0.12 loss. Management expects year-end cash near breakeven, while partner programs and a new Eli Lilly deal support a long-term cash-flow thesis.Seeking AlphaOmniAb Stock: A Self-Funding Option Book On 433 Partner Programs (NASDAQ:OABI)OmniAb reported Q3 2026 revenue of $4.0 million and a net loss of $15.7 million, with cash ending at $64.2 million. The company added Eli Lilly as a partner on an ion channel program, with potential payments up to $370 million. Management expects 2026 revenues of $35-39 million and ending cash of $53-57 million.MarketBeatOmniAb (NASDAQ:OABI) Releases Earnings Results, Beats Expectations By $0.01 EPSOmniAb reported Q3 EPS of -$0.12, beating estimates by $0.01, with revenue of $3.99 million. The company raised its 2026 revenue guidance to $35-39 million and signed an Eli Lilly license with up to $370 million in milestones. Stock fell 3% to $5.07.MarketBeatOmniAb Q3 Earnings Call HighlightsOmniAb reported Q3 revenue of $4.0 million, up from $2.2 million, and a net loss of $15.7 million. The company raised its 2026 revenue guidance to $35-39 million and expects to finish the year with $53-57 million in cash. It also highlighted a new Lilly licensing deal with potential up to $370 million in milestones.ChartmillOmniAb Inc. (NASDAQ:OABI) Q3 2026 Revenue Beat and Raised Guidance Offset by Sell-the-News PressureOmniAb reported Q3 2026 revenue of $3.99 million, beating consensus, and a net loss of $15.7 million, better than expected. The company raised its full-year revenue guidance to $35-39 million, but shares fell about 15.3% in premarket trading. Management expects xPloration revenue to double in 2027 and 2028.Quiver QuantitativeOMNIAB ($OABI) Releases Q3 2026 Earnings | OABI Stock NewsOMNIAB reported Q3 2026 earnings of -$0.12 per share, matching estimates, and revenue of $3.99M, beating estimates by $427,865. Seven institutional investors added shares while 43 reduced positions in the most recent quarter.TradingViewOmniAb Q3 2026 Earnings Call Is LiveOmniAb's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.TradingViewOmniAb Raises 2026 Revenue Outlook After Third-Quarter Revenue Grows to $4.0 MillionOmniAb reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million, and a net loss of $15.7 million. The company raised its full-year revenue guidance to $35-39 million and expects year-end cash of $53-57 million. It also entered a global collaboration with Eli Lilly for an ion channel program.The future of tradingOmniAb Raises 2026 Revenue and Cash GuidanceOmniAb raised its 2026 revenue and cash guidance, citing continued business performance. xPloration revenue is expected to reach $2–3 million, double in 2027, then double again in 2028. Higher instrument sales and consumables boosted third-quarter revenue, with recurring revenue expected to become a long-term growth driver.